Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer

NCT00807859 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00807859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00807859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
March 9, 2009
Completion date
October 19, 2015
Enrollment
65 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, breast tumors, cancer, locally recurrent and metastatic breast cancer, metastases, metastatic cancer, oncology, solid tumors, tumors